Pre-surgical treatment of uterine myomas with LH-RH agonists.
Twenty-five non-menopausal women with uterine myomas were treated with LHRH-analogues for 3-6 months. An average reduction of 40% in uterine volume was observed. One patient refused to complete her therapy, three had no more menses after the interruption of treatment, nine underwent myomectomy within four weeks of their final administration, while in 12 cases hysterectomy was performed. In all cases the decrease in uterine volume induced by the analogue allowed a more limited intervention and prevented excessive blood loss.
D'Addato
F
F
University of Turin, Vercelli Midwifery School, Ospedale S. Andrea, Italy.
Repinto
A
A
Andreoli
C
C
D000280:Administration, Inhalation; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002064:Buserelin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007044:Hysterectomy; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D016729:Leuprolide / Q000008:administration & dosage; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D017329:Triptorelin Pamoate; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery
D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; D002064:Buserelin